Logo

PharmaShots Weekly Snapshots (June 27 – July 01, 2022)

Share this
PharmaShots Weekly Snapshots (June 27 – July 01, 2022)

PharmaShots Weekly Snapshots (June 27 – July 01, 2022)

Inceptor Bio Enters into Collaboration with the University of Minnesota for the Development of iPSC Platform to Treat Cancer

Published: July 1, 2022 | Tags: Inceptor Bio, University of Minnesota, iPSC, Platform, Cancer, Biotech
Sensorion’s SENS-401 Receives Australia’s Approval for the Initiation of Proof-of-Concept Trial to Treat Hearing Impairment

Published: July 1, 2022 | Tags: Sensorion, Sens-401, Hearing Impairment, Regulatory, Proof-of-Concept Trial, US, FDA, EMA, Australia, France

Pfizer Reports NDA Submission of Paxlovid to the US FDA for the Treatment of COVID-19

Published: July 1, 2022 | Tags: Pfizer, Paxlovid, nirmatrelvir, ritonavir, Covid-19, Regulatory, EPIC-HR, EPIC-SR, US FDA 
Sanofi Pauses Patient Enrollment in P-III Studies of Tolebrutinib for the Treatment of Multiple Sclerosis and Myasthenia Gravis in the US

Published: July 1, 2022 | Tags: Sanofi, Tolebrutinib, Multiple Sclerosis, Myasthenia Gravis, Clinical Trial, P-III Studies, US

Blueprint Medicines Signs $1.25B Agreement with Sixth Street & Royalty Pharma in Exchange for Royalties of Ayvakit and Gavreto

Published: July 1, 2022 | Tags: Blueprint Medicines, Sixth Street, Ayvakit, Gavreto, Thyroid Cancers, Pharma, $1.25B, Financing Agreement, Royalties

Takeda Reports Results of Takhzyro (lanadelumab) in P-III (SPRING) Study for the Prevention of HAE Attacks in Children Aged 2 to <12 Years

Published: July 1, 2022 | Tags: Takeda, Takhzyro, lanadelumab, Hereditary Angioedema Attacks, Clinical Trial, P-III, SPRING Study

AstraZeneca Reports Results of Imfinzi in P-III (AEGEAN) Trial for the Treatment of Non-Small Cell Lung Cancer

Published: June 30, 2022 | Tags: AstraZeneca, Imfinzi, Non-Small Cell Lung Cancer, Clinical Trial, P-III, AEGEAN

Astellas Entered into an Exclusive License Agreement with Generian to Develop and Commercialize Novel Small Molecules for Undruggable Indications

Published: June 30, 2022 | Tags: Astellas, Generian, Mitobridge, Small Molecules, Pharma

Ascentage Reports the US FDA’s Acceptance of IND Application for APG-5918 to Treat Solid Tumors and Hematologic Malignancies

Published: June 30, 2022 | Tags: Ascentage, APG-5918, Solid Tumors, Hematologic Malignancies, Regulatory, US, FDA, IND

GBT Reports Initiation of the P-II/III Study of GBT601 for the Treatment of Sickle Cell Disease

Published: June 30, 2022 | Tags: GBT, GBT601, Sickle Cell Disease, Clinical Trial, P-II, P-III, EU, Middle East, South America, US

Merck Reports the Launch of Merck Digital Sciences Studio to Support Early-Stage Biomedical Startups

Published: June 30, 2022 | Tags: Merck, New Jersey Innovation Institute, Merck Digital Sciences Studio, Regulatory

Jaguar Entered into a Licence Agreement with SynWorld to Commercialise Canalevia in China to Treat Diarrhea in Dogs

Published: June 30, 2022 | Tags: Jaguar, SynWorld, Canalevia, Diarrhea, Pharma, China

Oculis Reports the First Patient Enrollment of OCS-01 in P-III (OPTIMIZE) Trial for the Treatment of Inflammation and Pain Following Cataract Surgery

Published: June 29, 2022 | Tags: Oculis, OCS-01, Inflammation, Pain, Cataract Surgery, Clinical Trial, P-III, OPTIMIZE Trial,

Iktos Collaborated with Galapagos to Discover Optimised Lead Therapies Using AI Technology

Published: June 29, 2022 | Tags: Iktos, Galapagos, Optimised Lead Therapies, AI Technology, Pharma

Beyond Air’s LungFit PH Receives the US FDA’s Approval for the Treatment of Hypoxic Respiratory Failure in Term and Near-Term Neonates

Published: June 29, 2022 | Tags: Beyond Air, LungFit PH, Hypoxic Respiratory Failure, Regulatory, MedTech, Near-Term Neonates, US, FDA, Approval

Jazz Reports Results of Nabiximols Oromucosal Spray in P-III (RELEASE MSS1) Trial for the Treatment of Multiple Sclerosis Spasticity

Published: June 29, 2022 | Tags: Jazz, Nabiximols Oromucosal Spray, Multiple Sclerosis Spasticity, Clinical Trial, P-III, RELEASE MSS1 Trial

Astellas Collaborated with Sutro Biopharma to Advance Novel Immunostimulatory Antibody-Drug Conjugates for Cancer

Published: June 29, 2022 | Tags: Astellas, Sutro Biopharma, Antibody-Drug Conjugates, Cancer, Pharma

NewAmsterdam Entered into an Exclusive License Agreement with Menarini Group to Commercialize Obicetrapib for Cardiovascular Diseases in the EU

Published: June 29, 2022 | Tags: NewAmsterdam, Menarini Group, Obicetrapib, Cardiovascular Diseases, Pharma, EU

Kite’s Yescarta (axicabtagene ciloleucel) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma

Published: June 28, 2022 | Tags: Kite, Yescarta, axicabtagene ciloleucel, Follicular Lymphoma, Regulatory, EC, Approval

AstraZeneca and Merck Receive CHMP Positive Opinion of Lynparza (olaparib) as Adjuvant Treatment for HER2-Negative High-Risk Early Breast Cancer

Published: June 28, 2022 | Tags: AstraZeneca, Merck, Lynparza, Olaparib, Breast Cancer, Regulatory, CHMP

Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at EAN 2022

Published: June 28, 2022 | Tags: Novartis, Kesimpta, ofatumumab, Relapsing Multiple Sclerosis, Clinical Trial, P-III, ASCLEPIOS I/II, ALITHIOS, Open-Label Extension Trial

Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia

Published: June 28, 2022 | Tags: Basilea, Ceftobiprole, Staphylococcus Aureus Bacteremia, Clinical Trial, P-III, ERADICATE Study

Astellas Reports the US FDA’s Clinical Hold on the P-I/II (FORTIS) Trial of AT845 for the Treatment of Adults with Late-Onset Pompe Disease

Published: June 28, 2022 | Tags: Astellas, AT845, Late-Onset Pompe Disease, Clinical Trial, US, FDA, Clinical Hold, P-I/II, FORTIS Trial

Kuria Entered into a Licensing Agreement with Scohia for SCO-116 to Treat Ophthalmic and Dermal Disease

Published: June 28, 2022 | Tags: Kuria, Scohia, SCO-116, Ophthalmic, Dermal Disease, Pharma

The US FDA Launches 5-Year Action Plan for Neurodegenerative Disease

Published: June 27, 2022 | Tags: US, FDA, Neurodegenerative Disease, Regulatory, Launches, 5-Year, Action Plan

AbbVie’s Rinvoq (upadacitinib) Receives the CHMP’s Recommendation for Approval to Treat Active Non-Radiographic Axial Spondyloarthritis

Published: June 27, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, Non-Radiographic Axial Spondyloarthritis, Regulatory, CHMP, Approval

Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

Published: June 27, 2022 | Tags: Ascletis, ASC22, envafolimab, Chronic Hepatitis B, Clinical Trial, P-IIb Trial, EASL, ILC, 2022

Intellia and Regeneron Present Updated Interim Data of NTLA-2001 in P-I Study for the Treatment of Transthyretin Amyloidosis at EASL 2022

Published: June 27, 2022 | Tags: Intellia, Regeneron, NTLA-2001, Transthyretin Amyloidosis, Clinical Trial, P-I Study, EASL 2022

BMS’ Breyanzi (lisocabtagene maraleucel) Receives the US FDA’s Approval for the Treatment of Large B-cell Lymphoma

Published: June 27, 2022 | Tags: BMS’ Breyanzi, lisocabtagene maraleucel, Large B-cell Lymphoma, Regulatory, US, FDA, Approval

Ipsen Entered into a Definitive Merger Agreement to Acquire Epizyme for ~$247M

Published: June 27, 2022 | Tags: Ipsen, Epizyme, Tazverik, rituximab, lenalidomide, EZM0414, Cancer, Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Follicular lymphoma M&A, Acquire, Epizyme, ~$247M

Related Post: PharmaShots Weekly Snapshots (June 20 – 24, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions